1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Fully Funded Biotech Plans Proof-Of-Concept In Man by End-2025

 
• By Sten Stovall

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile: ADCendo
uPARAP is overexpressed on the cell surface of several cancers • Source: Alamy

Danish biotech ADCendo ApS believes it can create a pipeline of antibody-drug conjugates targeting the novel cancer target uPARAP, bringing a lead candidate into clinical trials probably by 2023 using funds raised last month through a €51m ($62m) series A financing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 
• By Elizabeth Cairns

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Major Cash Injection Advances Augustine’s HDAC6 Hopes

 
• By Kevin Grogan

The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.

Roche Adds To Its Antibody Armoury With OBT Alliance

 
• By Kevin Grogan

Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.